Isnes, Belgium (July 16, 2014) – iSTAR Medical SA, a privately held ophthalmic device company, announced today that Michel Vanbrabant has been appointed Chief Executive Officer and member of the Board of Directors.
Mr. Vanbrabant joins iSTAR from Reva Medical Inc., where he was Managing Director, International. He brings more than two decades of experience in the medical device industry, including positions at PneumRx Inc., St Jude Medical Corp and Guidant Corp. Michel Alvarez, founder of iSTAR and former CEO, has left the company to pursue other career opportunities.
About Glaucoma and STARfloTM
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it is estimated that 80 million people worldwide will have the disease. Elevated intraocular pressure is considered a major risk factor for Glaucoma and its progression.
STARflo is a non-degradable, precision-pore, implant made from STAR® Biomaterial. It is designed to operate as a bleb-free, micro-porous drainage system to reduce intraocular pressure (IOP) in patients suffering from open angle glaucoma by augmenting the eye’s natural uveoscleral outflow. STARflo received CE Mark approval in 2012 and is currently available through distributors in select countries.